Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

16 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Curcumin on expression profile of Schistosoma mansoni adult worms

ABSTRACT: Transcriptional profiling of Curcumin treated S. mansoni adult worms (15uM of Curcumin in DMSO during 24h) vs. Non-treated S.mansoni adult worms (DMSO during 24h) Two conditions (treated vs. Non-treated) with four biological samples of treated worms (Curcumin 1, 2, 3 and 4) and four biological samples of non-treated worms (Control 1, 2, 3 and 4). For each sample (four treated and four non-treated) were performed two technical replicas.

ORGANISM(S): Schistosoma mansoni

SUBMITTER: Katia Oliveira

PROVIDER: E-GEOD-37647 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Effect of Curcumin on expression profile of Schistosoma mansoni adult worms

Project description:Transcriptional profiling of Curcumin treated S. mansoni adult worms (15uM of Curcumin in DMSO during 24h) vs. Non-treated S.mansoni adult worms (DMSO during 24h)

2012-12-30 | GSE37647 | GEO

Effect of MG132 on expression profile of Schistosoma mansoni adult worms

Project description:Transcriptional profiling of MG132 treated S. mansoni adult worms (50uM of MG132 in DMSO during 24h) vs. Non-treated S.mansoni adult worms (DMSO during 24h) Two conditions (treated vs. Non-treated) with four biological samples of treated worms (MG132 1, 2, 3 and 4) and four biological samples of non-treated worms (Control 1, 2, 3 and 4). For each sample (four treated and four non-treated) were performed two technical replicas.

2014-12-16 | GSE57722 | GEO

Transcriptome analysis of inhibitor-treated schistosome female

Project description:Transcriptional profiling of S. mansoni adult females treated with Herbimycin A (4.5 ÂµM ) or TGF beta receptor type I kinase inhibitor (TRIKI, 300 nM) or a combined treatment with both inhibitors (Herbimycin A 4.5ÂµM and TRIKI 300nM) vs. Non-treated S.mansoni adult females (DMSO during 48h) Two conditions (treated vs. Non-treated) with three biological samples of treated worms (Herbimycin, TRIKI or Herb+TRIKI) and in parallel other three biological samples of non-treated worms (DMSO) for each treatment condition. For each sample (three treated and three non-treated for each inhibitor combination) were performed two technical replicas.

2013-05-30 | E-GEOD-39732 | biostudies-arrayexpress

TGF-beta treated Schistosoma mansoni

Project description:Transcriptional profiling of TGF-beta treated Schistosoma mansoni adult worms vs. Non-treated Schistosoma mansoni adult worms Two conditions (treated vs. Non-treated) with three biological samples of treated worms (TGF1, 4 and 5) and two biological samples of non-treated worms that were pooled into a single sample (pool). For each sample (three treated or polled non-treated) were performed four technical replicas

2012-02-20 | E-GEOD-27050 | biostudies-arrayexpress

Transcriptome analysis of inhibitor-treated schistosome female

Project description:Transcriptional profiling of S. mansoni adult females treated with Herbimycin A (4.5 µM ) or TGF beta receptor type I kinase inhibitor (TRIKI, 300 nM) or a combined treatment with both inhibitors (Herbimycin A 4.5µM and TRIKI 300nM) vs. Non-treated S.mansoni adult females (DMSO during 48h)

2013-05-30 | GSE39732 | GEO

Competence for reprogramming sex

Project description:We used RNA-Seq to compare transcriptomes of chemical reprogramming competent worms versus worms not competent for chemical reprogramming. We also performed RNA-seq during a time course of chemical reprogramming. Three replicates of each of two reprogramming non-competent strains and three replicates of each of two reprogramming competent strains were collected. For the time course, five time points were analyzed (1, 2, 4, 6, and 18 hours) in either DMSO or DMSO + U0126 in three genotypes (non-reprogramming competent worms, reprogramming competent, and wildtype worms).

2014-09-10 | E-GEOD-54030 | biostudies-arrayexpress

Transcription profiling of human HL-60 leukemia cells after treatment with Curcumin and TCDD

Project description:Curcumin has antileukemic potential that is mediated by dfifferent pathways. Because we could not confirm that the Arylhydrocarbonreceptor, a ligand activated transcription factor, is involved in curcumins antileukemic effects, we performed microarray experiments to have an overall screening of the pathways affected by curcumin in HL-60 cells. We identified an involvement of the vitamin D receptor in the effects of curcumin on HL-60 cells by comparing our results with other experiments. Experiment Overall Design: HL-60 cells were treated for 24h with 100 ÂµM curcumin, 10 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), or 0.5 % DMSO as control.

2009-06-01 | E-GEOD-16160 | biostudies-arrayexpress

Effect of 35d and curcumin treatment on gene expression in GR6 cells

Project description:To investigate gene expression changes by 35d and curcumin, we treated 1 uM 35d and curcumin for 24h in GR6 cells. We then performed gene expression profiling analysis using data obtained from RNA-seq of untreated and treated cells

2023-09-08 | GSE215786 | GEO

Gene expression analysis of Neoechinulin B (NeoB)-treated Huh7.5.1 cells

Project description:Huh-7.5.1 cells were treated with 0.2% DMSO, 20 microM NeoB for 24 h. Treatment with 0.2% DMSO for 24h was prepared as non-treated Huh7.5.1 cells. Huh7.5.1 cells were kindly provided by Prof. Francis Chisari at The Scripps Research Institute.

2015-08-31 | GSE63026 | GEO

NAD+ and PPAR-modifying drugs in a C. elegans model of respiratory chain complex I deficiency

Project description:The gas-1(fc21) mutation affects the 49 kD subunit of complex I, decreasing the rate of complex I-dependent oxidative phosphorylation. This is a model for human mitochondrial respiratory chain disease. NAD+ and PPAR-modifying drugs may confer benefits with respect to lifespan in these short-lived mutant worms. Analysis of gas-1(fc21) electron transport chain complex I mutants treated either starting in development or in young adulthood only with nicotinic acid (1 mM), resveratrol (50 microM), rosiglitazone (5 mM) or fenofibrate (14 microM) is presented. The goal is to detect transcriptional changes in clusters of genes using gene set enrichment analysis to explain treament effects in these mutant worms. Four biological replicates were performed for each treatment condition (nicotinic acid, resveratrol, rosiglitazone, and fenofibrate) for each drug beginning either in development or in young adulthood for gas-1 mutant worms, i.e., 8 treated samples in total. At most one outlier was excluded from each analysis. Untreated N2 and gas-1 in each of the control solvents (S-basal, for nicotinic acid, and 1% DMSO, for resveratrol, rosiglitazone, and fenofibrate) were also analyzed; at least 3 replicates of each were included. These were used as sources of total RNA, each for hybridization to a single Affymetrix whole-genome microarray. Analysis was performed to reveal transcriptional changes related to mutantion and/or drug treatment effects.

2014-08-13 | E-GEOD-57626 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data